An opportunity to participate in future cancer research studies
The Exactis Personalize My Treatment (PMT) program is a pan-Canadian oncology initiative in which participants consent to provide blood, tissue samples and clinical data for cancer research.
As a cancer patient, your tumour tissue, blood samples and clinical data contain valuable information that may help advance cancer research. Each cancer has unique molecular properties, also called a “molecular profile.”
Determining the molecular profile of your tumour could accelerate the development of new treatments targeting tumours with specific molecular profiles.
The main goals of PMT are to:
Facilitate and accelerate the development of better diagnostic and screening tests, and better treatments for cancer patients
Support cancer research by building a large collection of cancer samples and data to which researchers will be able to request access
Match patients to available clinical trials specific to the molecular profile of their tumour and/or type of cancer
What are the benefits?
Participating in PMT offers no direct benefit to you. Your participation will contribute to the advancement of cancer research.
What are the risks?
Participating in PMT poses no additional physical risks, since no procedures are done solely for PMT.
If samples are collected for PMT during a routine procedure (such as a biopsy or a blood draw), this will add a few minutes to the procedure. The risks are the same as associated with the routine procedure.
As in any research project, there is a small risk of participant identification. Exactis takes measures to minimize this risk.
Patients participating in the PMT initiative, consent to:
Provide tumour tissue or other biospecimens for molecular profiling
Share their coded molecular and clinical data
Be contacted for clinical trials or other research
Be followed through their disease trajectory
What am I consenting to?
If you choose to participate in PMT, you consent to:
Provide blood or tissue samples collected during standard of care procedures
Allow access to relevant clinical and molecular information such as your cancer type and treatment history
Be contacted for possible participation in a clinical trial or to provide additional information or samples
Can I withdraw my consent?
Participation in PMT is completely voluntary. You can withdraw from PMT at any time by informing the Principal Investigator at your hospital. You are not required to give any reasons. Withdrawing from PMT will have no effect on your current or future care.
How is my privacy protected?
Precautions are taken to protect your privacy and confidentiality:
Your personal identifying information will only be available to authorized personnel
within your hospital
Your personal identifying information will be replaced by a code before your data and
samples are stored in the PMT Platform or shared with researchers
No evidence of participation in PMT will appear in your medical record
I am a cancer patient. How can I sign up for PMT?
Cancer patients at hospitals where PMT is active can ask their oncologist about participating in PMT (see list of active locations below). Your oncologist can see if you would be a candidate for PMT and can tell you more about what your participation would involve. Exactis Innovation cannot offer advice on how to treat your cancer – speak to your oncologist about your best treatment options. Sample profiling and clinical trial matching is not guaranteed for all patients.
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Contact: Tracy Xu Tracy.Xu@albertahealthservices.ca
Principal Investigator: Gwyn Bebb, MD
Centre hospitalier universitaire Dr-Georges-L.-Dumont
Moncton, New Brunswick, Canada
Contact: Stéphanie Crapoulet 506-862-4221
Principal Investigator: Eve St-Hilaire, MD
The Moncton Hospital
Moncton, New Brunswick, Canada
Contact: Ian Chute, MSc Ian.Chute@HorizonNB.ca
Principal Investigator: Mahmoud Abdelsalam, MD
The Ottawa Hospital
Ottawa, Ontario, Canada
Contact: Lenah Mukhtar email@example.com
Principal Investigator: John Hilton, MD
Odette Cancer Centre - Sunnybrook Hospital
Toronto, Ontario, Canada
Contact: Mark Gichuru firstname.lastname@example.org
Principal Investigator: Helen MacKay, MD
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Contact: Renée Bernatchez email@example.com
Principal Investigator: Fred Saad, MD
Jewish General Hospital
Contact: Caterina Marcangione firstname.lastname@example.org
Principal Investigator: Mark Basik, MD
Centre hospitalier universitaire de Québec - Université Laval
Québec, Quebec, Canada
Contact: Jean-Charles Hogue, PhD Jean-Charles.Hogue@crchudequebec.ulaval.ca
Principal Investigator: Louise Provencher, MD
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Contact: Noémie Poirier email@example.com
Contact: Suzanne Maltais firstname.lastname@example.org
Principal Investigator: Julie Carrier, MD
CIUSSS MCQ (Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-Centre-du-Québec)
Centre Hospitalier Affilié Universitaire Régional
Trois-Rivières, Quebec, Canada
Victoriaville, Quebec, Canada
Contact: Marie-Eve Caron email@example.com
Principal Investigator: François Vincent, MD
1001 Décarie Blvd
Contact: Jessica Mancuso, firstname.lastname@example.org
PI: Dr Jonathan Spicer, email@example.com